Donald J. Elmer, CEO and Chairman of the Board
Mr. Elmer is the managing general partner of Pacific Horizon Ventures. He is currently a board member of ViaCyte, Inc. He has extensive prior board experience and has successful operational experience over a twelve-year period in early-stage technology companies, including Cascadia Technology Corporation-a medical electronics company-and Cygnet Systems Corporation-a software developer. Mr. Elmer received his M.A. from the University of Pennsylvania.
Jean-Pierre Laurent, Ph.D., Chief Operating Officer
Jean-Pierre Laurent has extensive experience in applied biochemisty. He is co-founder of Rasiris, a research stage drug development company formed in 2003 and has served as its President and Chief Executive Officer. As a Principal at Pacific Horizon Ventures, Dr. Laurent is involved in both the evaluation and post-investment follow-up of the firm's biotechnology investments. Dr. Laurent earned a B.S. in biology from Université des Sciences et Techniques de Lille and a Ph.D. in Population Biology & Ecosystems at Université des Sciences et Techniques du Languedoc. He first came to the U.S. to learn applied biochemistry in infectious diseases, which he practiced for seven years in both protozoan and prokaryotic systems.
David A. Krekel, Chief Financial Officer
Mr. Krekel is a principal at Pacific Horizon Ventures where he has been involved in portfolio company oversight and management for several companies, including Koronis, Illumigen Biosciences, ViaCyte, and iScience Interventional. Prior to joining Pacific Horizon in 2003, Mr. Krekel worked at Virginia Mason Medical Center where he had operational responsibility for outpatient surgery groups. Mr. Krekel received his B.S. in Chemistry from Harvey Mudd College and his M.B.A. from the University of Washington.
Jeffrey J. Miller, Ph.D., Intellectual Property Team Leader
Dr. Miller received a Ph.D. in biophysics from UCLA and UC Santa Cruz in 1976. He earned a law degree and focused his intellectual property practice in biotechnology. Following a partnership at Seed & Berry in Seattle, he joined NeoRx in 1987 as an executive officer and was responsible for all aspects of FDA approval and commercialization of NeoRx's first product. Nine years later he joined Ostex International as chief strategy officer followed by two years as CEO of Reprogen, a functional genomics company. For the next five years Dr. Miller served as senior vice president of aQuantive, Inc. an internet technology company. Presently, Dr. Miller is on the board of directors of AmKor Pharma and Tissue Repair Company. Dr. Miller's career achievements include obtaining the first US patent for an animal on behalf of the University of Washington, structuring and negotiating numerous multimillion dollar technology license agreements, and managing legal aspects of more than $250M in private and public debt and equity transactions.
Murray Lee, Asian Foreign Market Team Leader
Mr. Lee has had an extensive business career developing global markets for a multiplicity of products. For the last 20 years, he has successfully developed and overseen a global trading and distribution company. He has lived in China for 15 years and speaks Mandarin Chinese. Mr. Lee has a BA in Economics from UCLA and a Masters in International Management from Thunderbird School of Global Management.